Jama Cardiology

JAMA Cardiology (jama-cardiology)

Journal positioning

JAMA Cardiology is a JAMA Network specialty journal for cardiovascular clinical research relevant to the practice of cardiology and cardiovascular medicine. It favors rigorous, practice-relevant work — randomized cardiovascular trials, large outcomes and registry analyses, prevention and risk-factor studies, and cardiac imaging studies tied to clinical outcomes — with JAMA's emphasis on hard endpoints, absolute risk, and direct relevance to patient care. Mechanistic bench cardiology, small physiology studies with surrogate-only readouts, and imaging-technique papers with no outcome link are a weak fit. This skill is a fit / venue-selection / re-framing aid; it is not clinical or regulatory advice and does not replace the journal's current instructions for authors. Before submitting, re-check the live JAMA Cardiology author instructions.

When to trigger

• The author names JAMA Cardiology for a cardiovascular clinical, outcomes, or imaging-outcome study and wants a fit/framing check.
• A cardiovascular study must be re-framed around a hard clinical endpoint (MACE, mortality, hospitalization) for a practicing-cardiology audience.
• The author is choosing between JAMA Cardiology, JAMA, and a cardiology-society journal.
• The author needs the journal's reporting-guideline, registration, and desk-reject expectations for cardiovascular work.

Scope & topic fit

• Randomized cardiovascular trials (drug, device, procedural, or strategy) with clinically meaningful endpoints, including pragmatic and de-implementation designs.
• Large outcomes, registry, and claims analyses on cardiovascular events, heart failure, arrhythmia, and structural/interventional outcomes.
• Cardiovascular prevention, risk-factor, lipid, hypertension, and population cardiovascular-health studies.
• Cardiac imaging (echo, CMR, CCT, nuclear) studies where the contribution is a clinical-outcome or prognostic association, not a pure imaging technique.
• Cardiovascular biomarker and risk-prediction studies validated against outcomes.
• Systematic reviews and meta-analyses answering a focused cardiovascular question.

Method & evidence bar

• Trials must be adequately powered with a prespecified primary endpoint, ideally a hard clinical outcome or validated composite (with the composite components reported); surrogate-only endpoints need strong justification.
• The applicable reporting guideline and checklist are required: CONSORT for trials (with device/procedure extensions where relevant), STROBE for observational studies, PRISMA for systematic reviews; risk-model work should follow TRIPOD-style reporting.
• Trials require prospective registration; registration number, protocol, and statistical-analysis plan are expected, including for device and procedural trials.
• Effect estimates need absolute and relative measures, confidence intervals, adequate follow-up, and adjudicated endpoints where feasible.
• Registry/observational claims must address confounding by indication, immortal-time bias, and missing data; causal language must match the design.
• Risk-prediction and biomarker claims need internal and ideally external validation, calibration, and discrimination metrics.

Structure & house style

• JAMA Network format with a structured abstract and a Key Points box; re-check current article types (Original Investigation, Brief Report, Research Letter, etc.) and limits on the live guide.
• The introduction frames a focused, practice-relevant cardiovascular question; the discussion states the clinical implication and absolute benefit/harm plainly.
• Tables/figures follow JAMA Network statistical-reporting standards; CONSORT/STROBE flow diagrams, event-free survival curves with numbers at risk, and adjudicated-event tables are expected where applicable.
• Supplements carry the protocol, SAP, endpoint definitions, and additional analyses.